3-amino-5-bromothiophene-2-carboxylic acid [3-methoxy-4-(2-pyrrolidin-1-ylethoxy)-phenyl]amide | 947176-22-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-amino-5-bromothiophene-2-carboxylic acid [3-methoxy-4-(2-pyrrolidin-1-ylethoxy)-phenyl]amide
• 英文别名: 3-Amino-5-bromothiophene-2-carboxylic acid [3-methoxy-4-(2-pyrrolidin-1-ylethoxy)phenyl]amide；3-amino-5-bromo-N-[3-methoxy-4-(2-pyrrolidin-1-ylethoxy)phenyl]thiophene-2-carboxamide
• CAS: 947176-22-9
• 化学式: C₁₈H₂₂BrN₃O₃S
• 分子量: 440.361
• InChiKey: SEDVZKPLWHRFJY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  26
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  105
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  3-amino-5-bromothiophene-2-carboxylic acid [3-methoxy-4-(2-pyrrolidin-1-ylethoxy)-phenyl]amide 在 bis[1,2-bis(diphenylphosphino)ferrocene]-palladium(0) 、 sodium carbonate 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 1.5h， 生成 6-(4-Fluorophenyl)-3-[3-methoxy-4-(2-pyrrolidin-1-ylethoxy)phenyl]thieno[3,2-d]pyrimidin-4-one
  参考文献：
  名称：

  The discovery and optimization of pyrimidinone-containing MCH R1 antagonists

  摘要：

  Optimization of a series of constrained melanin-concentrating hormone receptor 1 (MCH RI) antagonists has provided compounds with potent and selective MCH R1 activity. Details of the optimization process are provided and the use of one of the compounds in an animal model of diet-induced obesity is presented. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.07.008
• 作为产物：
  描述：

  5-Bromo-N-[3-methoxy-4-(pyrrolidin-1ylethoxy)phenyl]-3-nitrothiophene-carboxamide 在 tin(ll) chloride 作用下， 以 乙醇 为溶剂， 反应 0.5h， 生成 3-amino-5-bromothiophene-2-carboxylic acid [3-methoxy-4-(2-pyrrolidin-1-ylethoxy)-phenyl]amide
  参考文献：
  名称：

  The discovery and optimization of pyrimidinone-containing MCH R1 antagonists

  摘要：

  Optimization of a series of constrained melanin-concentrating hormone receptor 1 (MCH RI) antagonists has provided compounds with potent and selective MCH R1 activity. Details of the optimization process are provided and the use of one of the compounds in an animal model of diet-induced obesity is presented. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.07.008

文献信息

• NOVEL AMINO ALCOHOL-SUBSTITUTED ARYLTHIENOPYRIMIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS
  申请人：SCHWINK Lothar

  公开号：US20090076002A1

  公开（公告）日：2009-03-19

  The invention relates to amino alcohol-substituted arylthienopyrimidinones and their derivatives, and their physiologically tolerated salts and physiologically functional derivatives, their preparation, medicaments comprising at least one amino alcohol-substituted arylthienopyrimidinone of the invention or its derivative, and the use of the amino alcohol-substituted arylthienopyrimidinones of the invention and their derivatives as MCH antagonists.

  本发明涉及氨基醇取代的芳基噻唑嘧啶酮及其衍生物、其生理上可耐受的盐和生理功能衍生物、其制备方法、包含本发明中至少一种氨基醇取代的芳基噻唑嘧啶酮或其衍生物的药物以及将本发明中的氨基醇取代的芳基噻唑嘧啶酮及其衍生物用作MCH拮抗剂的用途。
• Amino alcohol-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments
  申请人：Schwink Lothar

  公开号：US08853208B2

  公开（公告）日：2014-10-07

  The invention relates to amino alcohol-substituted arylthienopyrimidinones having a formula I and their derivatives, and their physiologically tolerated salts and physiologically functional derivatives, their preparation, medicaments comprising at least one amino alcohol-substituted arylthienopyrimidinone of the invention or its derivative, and the use of the amino alcohol-substituted arylthienopyrimidinones of the invention and their derivatives as MCH antagonists.

  本发明涉及具有公式I及其衍生物的氨基醇取代芳基噻唑嘧啶酮，以及它们的生理耐受盐和生理功能衍生物、它们的制备方法、包含本发明中至少一种氨基醇取代芳基噻唑嘧啶酮或其衍生物的药物，以及将本发明中的氨基醇取代芳基噻唑嘧啶酮及其衍生物作为MCH拮抗剂的用途。
• WO2007/93365
  申请人：——

  公开号：——

  公开（公告）日：——
• The discovery and optimization of pyrimidinone-containing MCH R1 antagonists
  作者：Donald L. Hertzog、Kamal A. Al-Barazanji、Eric C. Bigham、Michael J. Bishop、Christy S. Britt、David L. Carlton、Joel P. Cooper、Alex J. Daniels、Dulce M. Garrido、Aaron S. Goetz、Mary K. Grizzle、Yu C. Guo、Anthony L. Handlon、Diane M. Ignar、Ronda O. Morgan、Andrew J. Peat、Francis X. Tavares、Huiqiang Zhou

  DOI：10.1016/j.bmcl.2006.07.008

  日期：2006.9

  Optimization of a series of constrained melanin-concentrating hormone receptor 1 (MCH RI) antagonists has provided compounds with potent and selective MCH R1 activity. Details of the optimization process are provided and the use of one of the compounds in an animal model of diet-induced obesity is presented. (c) 2006 Elsevier Ltd. All rights reserved.